Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma.

Abstract

The role of serum macrophage inflammatory protein-1 alpha (MIP-1alpha) in bone disease and survival was evaluated in 85 newly diagnosed multiple myeloma (MM) patients. MIP-1alpha was elevated in MM patients and correlated with the extent of bone disease, bone resorption markers and levels of soluble receptor activator of nuclear factor-kappaB (RANK) ligand. MIP-1alpha was also associated with survival; the 3-year probability of survival was 85% and 44% for MIP-1alpha levels below and above 48 pg/ml respectively (P = 0.021). This suggests that MIP-1alpha contributes to the pathogenesis of bone disease in MM and possibly in tumour growth, as reflected by its impact on survival.

• Authors: Evangelos Terpos, Marianna Politou, Richard Szydlo, John M Goldman, Jane F Apperley, Amin Rahemtulla
• Journal: British journal of haematology (Br J Haematol) Vol. 123 Issue 1 Pg. 106-9 (Oct 2003) ISSN: 0007-1048 [Print] England
• PMID: 14510950 (Publication Type: Journal Article)

Chemical References

• Biomarkers, Tumor
• Carrier Proteins
• Chemokine CCL3
• Chemokine CCL4
• Macrophage Inflammatory Proteins
• Membrane Glycoproteins
• RANK Ligand
• Receptor Activator of Nuclear Factor-kappa B
• TNFRSF11A protein, human
• TNFSF11 protein, human

Topics

• Adult
• Aged
• Biomarkers, Tumor (blood)
• Bone Resorption
• Carrier Proteins (blood)
• Chemokine CCL3
• Chemokine CCL4
• Female
• Humans
• Macrophage Inflammatory Proteins (blood)
• Male
• Membrane Glycoproteins (blood)
• Middle Aged
• Multiple Myeloma (blood, mortality, pathology)
• Probability
• RANK Ligand
• Receptor Activator of Nuclear Factor-kappa B
• Stem Cell Transplantation
• Survival Rate